Bacterial protoplast-derived nanovesicles for tumor targeted delivery of chemotherapeutics
Authors:
- 1 January 2017
- journal article
- Published by Elsevier in Biomaterials
- Vol. 113, 68-79
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health & Welfare, Republic of Korea (HI14C1277)
- National Research Foundation of Korea (NRF) (2015R1A2A1A10055961)
This publication has 44 references indexed in Scilit:
- Bio-inspired, bioengineered and biomimetic drug delivery carriersNature Reviews Drug Discovery, 2011
- Bacterial ghosts (BGs)—Advanced antigen and drug delivery systemVaccine, 2010
- Outer Membrane Vesicles Derived from Escherichia coli Induce Systemic Inflammatory Response SyndromePLOS ONE, 2010
- Delivery of foreign antigens by engineered outer membrane vesicle vaccinesProceedings of the National Academy of Sciences, 2010
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumorsNature Biotechnology, 2009
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer AgentsJournal of Liposome Research, 2008
- UnstableEscherichia coliL Forms Revisited: Growth Requires Peptidoglycan SynthesisJournal of Bacteriology, 2007
- Bacteria-mediated delivery of nanoparticles and cargo into cellsNature Nanotechnology, 2007
- Hepatotoxicity of ChemotherapyThe Oncologist, 2001